WELCOME MESSAGE

 

WHY ATTEND? - Alcohol related liver disease remains the most important cause of liver disease morbidity and mortality in Europe and North America and is therefore relevant to all hepatologists.


Dear Colleagues,

We would like to invite you to the EASL-AASLD joint meeting on Alcohol related Liver Disease, in which we will address topics on public health, diagnostic definitions, therapeutic advances and clinical endpoints in alcohol related liver disease and alcoholic hepatitis.

Alcohol related liver disease (ALD) is the most prevalent cause of advanced liver disease and liver related mortality in Western countries.

Research in ALD spans a wide spectrum from public health to basic science and despite being the ‘Cinderella’ disease area in hepatology, there have been a number of advances in recent years. We would like to take this opportunity to review with you the emerging data from clinical, translational and basic science studies in ALD. Furthermore, as pharmaceutical company interest in ALD begins to evolve we would encourage you to participate in discussions around the endpoints in clinical trials.

This conference will be a unique occasion to interact with experts and top-researchers, to get new ideas but also to contribute in the field of therapeutic development in ALD and alcoholic hepatitis. We hope that we will be able to create an atmosphere of interactions above all the scientific content.

As organising committee, we welcome you to this EASL-AASLD joint meeting on "Definition, therapeutic advances and clinical endpoints in alcoholic liver disease and alcoholic hepatitis"

 

The organisers

P-Mathurin-meilleure.jpg

Vijay Shah.jpg Gyongyi-Szabo-profile-pic.jpg Mark Thursz.jpg

Prof. Philippe Mathurin

Prof. Vijay Shah

Prof. Gyongyi Szabo

Prof. Mark Thursz

       

 

Key players             Conference objectives
  • FDA
  • EMA
  • NIAAA
  • Interested pharmaceutical companies
 
  • Attendees will be equipped with the most up-to-date evidence based practice information relevant to patients with alcohol related liver disease
  • The attendees will be familiar with the most important controversies in the field and how the experts are addressing these issues
  • The attendees will become aware of the rational behind new endpoints in clinical trials
  • Debate and set endpoints in clinical trials
  • Discuss and generate guidelines of best practice in alcohol related liver disease
Scientific Committee

Prof. Philippe Mathurin
France

 

Prof. Mark Thursz
United Kingdom

Prof. Vijay Shah
United States

Prof. Gyongyi Szabo
United States

Key Deadlines

Abstract
Submission

Up to & incl.
30 June 2017

Early
Registration

07 August 2017


REGISTRATION
Register and book your hotel accommodation now!
PRELIMINARY PROGRAMME
View the preliminary programme highlights or download PDF file.
Abstracts
ABSTRACT SUBMISSION
Abstract submission is now closed